- Home
- GT vs AGIO Comparison
GT vs AGIO Comparison
Compare GT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GT | AGIO |
|---|---|---|
| Founded | 1898 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GT | AGIO |
|---|---|---|
| Price | $9.16 | $28.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.36 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 5.3M | 1.6M |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,310,000,000.00 | $44,791,000.00 |
| Revenue This Year | N/A | $28.75 |
| Revenue Next Year | $0.53 | $139.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $6.51 | $22.24 |
| 52 Week High | $12.03 | $46.00 |
Technical Indicators
Market Signals| Indicator | GT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 49.14 |
| Support Level | $8.67 | $26.54 |
| Resistance Level | $9.01 | $29.44 |
| Average True Range (ATR) | 0.26 | 1.14 |
| MACD | -0.00 | 0.60 |
| Stochastic Oscillator | 77.02 | 67.69 |
Price Performance
Historical ComparisonAbout GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.